Designation is for treating retinitis pigmentosa, one of the most common types of inherited retinal disorders characterized by the loss of photoreceptor cells OpCT-001 is an iPSC-derived investigational cell therapy being clinically tested to treat retinitis pigmentosa Berlin, Germany, and Cambridge, MA, USA January 22, 2026 – Bayer AG and its wholly owned, independently […]
Designation enables preferred procedural treatment and review consultation by Japan’s Ministry of Health, Labor and Welfare Parkinson’s disease affects approximately 10 million people worldwide and 250,000 in Japan Berlin, Germany and Cambridge, MA, USA, December 17, 2025 – Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy […]
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants Secondary clinical efficacy endpoints related to motor outcomes remain stable compared to 24 months and continue to show positive trends from baseline Data were presented […]
BlueRock announced that the first patient has received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for Parkinson’s disease.
Berlin, Germany, and Cambridge, MA, USA July 8, 2025 – Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced that the first patient received the investigational therapy in CLARICO, a Phase 1/2a clinical […]
Cambridge MA, USA, APRIL 16, 2025 – BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced the publication of the 18-month data from its Phase 1 exPDite clinical trial for bemdaneprocel in the journal Nature. “The […]
Berlin, Germany, and Cambridge, MA, USA February 27, 2025 – Bayer AG and BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for […]
Phase III exPDite-2 trial follows completion and discussion of Phase I trial data with US FDA under Regenerative Medicine Advanced Therapy (RMAT) designation exPDite-2 is a randomized, sham surgery-controlled double-blind trial assessing efficacy and safety of bemdaneprocel in people living with moderate Parkinson’s disease […]
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by the loss of dopaminergic neurons in the brain. These neurons produce dopamine, a chemical that is needed to control movement and other functions. People with Parkinson’s have lower levels of dopamine and, as a […]
Inherited retinal diseases (IRDs) represent a diverse and complex group of genetic disorders affecting the retina—the light-sensitive layer of tissue at the back of the eye. Within the IRD umbrella are primary photoreceptor diseases, which specifically cause photoreceptor degradation or dysfunction. These cells are […]
